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Abstract
Introduction To tailor local treatment in breast cancer patients
there is a need for predicting ipsilateral recurrences after breast-
conserving therapy. After adequate treatment (excision with free
margins and radiotherapy), young age and incompletely excised
extensive intraductal component are predictors for local
recurrence, but many local recurrences can still not be
predicted. Here we have used gene expression profiling by
microarray analysis to identify gene expression profiles that can
help to predict local recurrence in individual patients.
Methods By using previously established gene expression
profiles with proven value in predicting metastasis-free and
overall survival (wound-response signature, 70-gene prognosis
profile and hypoxia-induced profile) and training towards an
optimal prediction of local recurrences in a training series, we
establish a classifier for local recurrence after breast-conserving
therapy.
Results Validation of the different gene lists shows that the
wound-response signature is able to separate patients with a
high (29%) or low (5%) risk of a local recurrence at 10 years
(sensitivity 87.5%, specificity 75%). In multivariable analysis the
classifier is an independent predictor for local recurrence.
Conclusion Our findings indicate that gene expression profiling
can identify subgroups of patients at increased risk of
developing a local recurrence after breast-conserving therapy.
Introduction
Breast-conserving therapy (BCT) is a well-established treat-
ment modality for early (stages I and II) breast cancer. The
treatment consists of complete surgical excision of the tumor
followed by whole breast irradiation. In multiple randomized tri-
als comparing BCT with mastectomy, their equality in overall
survival has been shown [1-7]. A large population-based Dan-
ish series showed that in different age categories (less than 35
years, 35 to 39 years, 40 to 44 years and 45 to 49 years) of
young patients, survival was not negatively influenced by BCT
[8]. However, local recurrence rates were significantly higher
after BCT than after mastectomy in all series. The standard
treatment for a local recurrence is a salvage mastectomy,
which negates the original cosmetic intentions of BCT. More
importantly, a recent meta-analysis by the Early Breast Cancer
Trialists' Collaborative Group showed a negative impact of a
local recurrence on survival [9]. They concluded: 'Differences
in local treatment that substantially affect local recurrence
rates would, in the hypothetical absence of any other causes
of death, avoid about one breast cancer death over the next 15
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years for every four local recurrences avoided, and should
reduce 15-year overall mortality.'
Identifying patients at high risk for local recurrence in advance
and individualizing treatment in these patients (for example, a
higher radiotherapy dose ('boost') or a primary mastectomy) is
desirable. Several risk factors for local recurrence have been
recognized [10-17]. Margin status, young age, an incom-
pletely excised extensive intraductal component and inade-
quate radiotherapy dose (boost) have been identified as
important risk factors for local recurrence [18]. Adjuvant sys-
temic treatment (chemotherapy or hormonal therapy) is known
to reduce the risk of a local recurrence [12,14,16].
Previous studies have shown the ability to predict distant-
metastasis-free and overall survival in breast cancer with the
use of microarray analysis [19-25]. Mechanisms of recurrence
in the breast are not necessarily the same as mechanisms
involved in distant metastasis. Theoretically, radioresistance of
the tumor cells would be an important factor in local recur-
rence after BCT but not necessarily in distant metastasis.
Previous analyses of gene expressions patterns in a series of
295 early-stage breast cancer patients have identified gene
expression signatures that powerfully predict the risk of distant
metastasis and mortality [22,23,26,27]. In the present study
we used a supervised approach to search for gene expression
signatures that predict the risk of local recurrence after BCT in
a series of 161 early-stage breast cancer patients.
Materials and methods
Tumor samples and patients
This analysis is based on previously reported gene expression
profiles of tumors from a series of 295 stage I and II breast
cancer patients treated at the Netherlands Cancer Institute
between 1984 and 1995 [23]. All patients were under 53
years of age at the time of diagnosis. For this study all the
patients from this series who received BCT (n = 161) were
selected. BCT consisted of a wide local excision and axillary
lymph node dissection followed by whole breast irradiation
(median dose 50 Gy, range 50 to 54 Gy; the use of 6, 8 or 18
MV photons depending on breast diameter); 144 patients
received a boost to a median dose of 15 Gy, 98 patients
received a low boost (14 to 18 Gy), and 46 patients received
a higher boost (20 to 26 Gy). The boost technique was deliv-
ered using 192I (iridium) implantation (88 patients), electrons
(31 patients) or photons (25 patients). Pathological margins
were assessed as free of tumor in 134 patients, focal involve-
ment by invasive carcinoma only in 3 patients, focal involve-
ment by ductal carcinoma in situ (DCIS) only in 5 patients, and
focal involvement by both DCIS and invasive carcinoma in 4
patients; in 8 patients there was more than focal involvement
of the margins by DCIS, or the degree of margin involvement
could not be determined with certainty. For four patients there
was invasive carcinoma at the margin, but the extent of involve-
ment could not be determined with certainty, and for three
patients this was the case for both invasive carcinoma and a
DCIS component. Of all 27 patients with any extent of involved
margins, 2 did not receive a boost, 6 received a low boost and
19 a high boost of radiotherapy. Follow-up assessment was at
least yearly, including mammography. Seventeen patients
developed a local recurrence; the resection margins of the pri-
mary tumor had been free of any tumor for 15 of these 17
patients. One patient who later developed a local recurrence
had focal involvement of the resection margins with invasive
carcinoma, and one patient had focal involvement with DCIS.
The 10-year local-recurrence-free percentage was 85%
(median follow-up for all patients was 7.7 years, and 8.5 years
for alive patients).
On the basis of the microarray identification number, patients
were alternately assigned to the training set (that is, develop-
ing a predictor of local recurrence) or to the validation set. This
was done separately for locally recurring and locally tumor-free
patients, thereby creating almost equal-sized sets with balanc-
ing for local recurrence.
Patient characteristics for both the training and validation
series are equally divided and are shown in Table 1. In Table 2
characteristics are listed for patients with and without a local
recurrence. A full clinical data sheet is available online as Addi-
tional file 1, on [28] and on the paper's home page [29].
Microarray procedures
RNA isolation, labeling of complementary RNA, and hybridiza-
tion to 25,000-element oliogonucleotide microarrays, and
measurement of expression ratios were performed as
described previously [23].
The microarray data for analysis of the 70-gene prognosis pro-
file were obtained with the use of the same 25,000-element
oligonucleotide array; the correlation coefficient of the expres-
sion of these 70 genes with the good prognosis profile was
calculated as reported previously [22]. The two other gene
lists used are derived from Stanford cDNA arrays [30]. The
correspondence between genes represented by Stanford
cDNA microarrays and Rosetta/NKI oligonucleotide microar-
rays were established by using Unigene identifiers (build 158,
release date 18 January 2003 for the wound signature, as this
was the original mapping carried out for the validation of the
wound signature [26]). The primary hypoxia analysis was per-
formed at a later time. We used build 172, release date 17 July
2004 [27]. Because of the relatively small number of genes,
probes on the Rosetta/NKI array that were mapped to the
same unigene cluster were averaged.
The entire expression database for all 295 patients is publicly
available online [28], as are the files containing the expression
ratios for the specific experiments (70 genes (Additional file 2),Available online http://breast-cancer-research.com/content/8/5/R62
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hypoxia signature (Additional file 3) and wound signature
(Additional file 4) [29].
Class prediction and gene selection de novo
The first method we used for predicting local recurrence is
PAM (prediction analysis for microarrays): class prediction as
described by Tibshirani and colleagues [31]. This method
shifts the mean expression level of each gene (possibly after
transformation) for each class (for example local recurrence)
towards the overall mean expression level for all classes by a
fixed standardized difference (shrunken centroids). The class
for which the shrunken centroid most closely reaches the
observed expression pattern of a certain patient by using a
Pearson correlation is then the predicted class for that patient.
For a given shrunken centroid only those genes for which the
shrunken means still differ from the overall mean will contribute
to the distance between centroids and any individual tumor
sample's expression pattern. The standardized difference, and
thereby the number of relevant genes, is chosen by minimizing
the prediction error using 10-fold balanced, leave-10%-out
cross-validation within the training set. The same method is
then used to predict classes for new samples (validation set).
Gene set enrichment analysis
Subramanian and colleagues [32] have described a method
that analyzes whether or not predefined gene sets (represent-
ing biological pathways) are coordinately and significantly
upregulated or downregulated between samples that repre-
sent different biological or clinical entities [32]. The program
corrects for multiple testing. We applied this method to our
data set and analyzed gene set C2 ('functional gene set'). The
software and gene set are available for download [33]. C2 rep-
resents 504 gene sets. Standard parameters were used for
the analysis. The threshold for false discovery rate is 25%
before a gene set is called significantly upregulated or down-
regulated.
Established gene expression profiles and methods of 
supervised analysis
The following previously established gene expression profiles
were used to find a classifier for local recurrence after BCT:
1. The wound-response gene expression signature is a char-
acteristic pattern of expression of a set of genes that have
been identified as being induced or repressed in response to
Table 1
Characteristics of patients in the training and validation series
Characteristic Training Validation All
No. of patients 81 80 161
Non-local recurrence 72 (89%) 72 (90%) 144 (89%)
Local recurrence 9 (11%) 8 (10%) 17 (11%)
Tumor size T1/T2 50/31 (62%/38%) 48/32 (60%/40%) 98/63 (61%/39%)
pN0/pN+ 46/35 (57%/43%) 44/36 (55%/45%) 90/71 (56%/44%)
Grade I/II/III 22/26/33 (27%/32%/41%) 21/28/31 (26%/35%/39%) 43/54/64 (27%/33%/40%)
Age <40 years 62 (77%) 64 (80%) 126
Follow-up (years) 7.87 7.56 7.69
Metastasis 26 (32%) 23 (29%) 49 (30%)
Chemotherapy 28 (35%) 30 (38%) 58 (36%)
Hormonal therapy 10 (12%) 8 (10%) 18 (11%)
ER+/ER- 66/15 (81%/19%) 55/25 (69%/31%) 121/40 (75%/25%)
Median RT dose (Gy) 50 50 50
Median boost dose (Gy) 15 15 15
Boost, yes/no 70/11 (86%/16%) 74/6 (93%/7%) 144/17 (89%/11%)
Margins infiltrating carcinomaa 73, 4, 4 (90%, 5%, 5%) 72, 3, 5 (90%, 4%, 6%) 145, 7, 9 (90%, 4%, 6%)
Margins DCISb 25, 48, 3, 5 (31%, 59%, 4%, 6%) 27, 41, 7, 5 (34%, 51%, 9%, 6%) 52, 89, 10, 10 (33%, 55%, 6%, 6%)
pN0, pathologically node negative; pN+, pathologically node positive; ER, estrogen receptor; RT, radiotherapy; DCIS, ductal carcinoma in situ.
aResults are given in the following sequence: radical, focally positive resection margin, extensively positive resection margin or positive resection 
margin not otherwise specified; bresults are given in the following sequence: no DCIS, radical, focally positive resection margin, extensively 
positive resection margin or positive resection margin not otherwise specified.Breast Cancer Research    Vol 8 No 5    Nuyten et al.
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bovine serum, a surrogate wound environment [30,34]. This
so-called 'core serum response' has shown to be a strong pre-
dictive factor for outcome in cancer (breast, head and neck,
lung and gastric) using metastasis-free and overall survival as
endpoints [26,30]. It is important to realize that a particular
pattern of expression of these genes, not just the genes them-
selves, predicts outcome.
2. The 70-gene prognosis profile was originally trained to pre-
dict metastasis within 5 years ('poor prognosis' group), or no
metastasis within 5 years ('good prognosis' group) [22].
3. The hypoxia profile is a gene expression classifier from an in
vitro  experiment in which epithelial cells are exposed to
hypoxia [27].
First, these gene expression profiles were used in their original
form and tested for their value in predicting local recurrence
after BCT in the complete set of 161 patients.
Second, we optimized these profiles by using the clinical data
on local recurrence.
Using the training data set, we calculated for each of the three
profiles the average pattern of expression of the genes that
comprised each profile, for patients who developed a local
recurrence (local recurrence profile or local recurrence cen-
troid). For all patients in the training and validation set we then
calculated the non-centralized Pearson correlation to each of
the three average patterns of expression (local recurrence pro-
file or local recurrence centroid). A correlation value between
-1 and +1 is thereby derived for all patients and indicates the
similarity in gene expression between an individual patient
(tumor) and the average gene expression of tumors from
patients in the training set who developed a local recurrence.
For each of the three signatures a plot of these correlation val-
ues (see Figure 1 for the core serum response genes) is drawn
for the training set and shows the difference in expression
between patients who developed a local recurrence and those
who did not. On the basis of the difference in the distribution
of these correlation values, we selected the maximal threshold,
misclassifying only one out of nine local recurrences in the
training set. Patients with a correlation value above the thresh-
old were classified as high-risk, and patients below the thresh-
old as low-risk. Except for the gene selection process, this is
the same procedure as followed by van't Veer and colleagues
[21]. The local recurrence profile and its associated threshold
value were subsequently validated on the validation set. The
Table 2
Clinical characteristics by local recurrence versus non local recurrence
Characteristic Non-local recurrence Local recurrence pa All
No. of patients 144 17 161
Tumor size T1/T2 86/58 (67%/33%) 12/5 (71%/29%) 0.46 98/63 (61%/39%)
pN0/pN+ 83/61 (58%/42%) 7/10 (41%/59%) 0.19 90/71 (56%/44%)
Grade I/II/III 41/47/56 (28%/33%/39%) 2/7/8 (12%/41%/47%) 0.16 43/54/64 (27/33/40%)
Age <40 years 28 (19%) 7 (41%) 0.074 35
Median follow-up (years) 7.68 9.31 0.014 7.69
Metastasis 40 (28%) 9 (53%) 0.004 49 (30%)
Chemotherapy 50 (35%) 8 (47%) 0.291 58 (36%)
Hormonal therapy 16 (11%) 2 (12%) 0.86 18 (11%)
ER+/ER- 109/35 (76%/24%) 12/5 (71%/29%) 0.42 121/40 (75%/25%)
Median RT dose (Gy) 50 50 0.47 50
Median boost dose (Gy) 15 15 0.22 15
Boost, yes/no 131/13 (91%/9%) 13/4 (76%/24%) 0.075 144/17 (89%/11%)
Margins infiltrating carcinomab 129, 6, 9 (90%, 4%, 6%) 16, 1, 0 (94%, 6%, 0%) 0.365 145, 7, 9 (90%, 4%, 6%)
Margins DCISc 49, 76, 9, 10 (34%, 53%, 6%, 7%) 3, 13, 1, 0 (18%, 76%, 6%, 0%) 0.65 52, 89, 10, 10 (33%, 55%, 6%, 6%)
pN0, pathologically node negative; pN+, pathologically node positive; ER, estrogen receptor; RT, radiotherapy; DCIS, ductal carcinoma in situ.
aCox univariate; bresults are given in the following sequence: radical, focally positive resection margin, extensively positive resection margin or 
positive resection margin not otherwise specified; cresults are given in the following sequence: no DCIS, radical, focally positive resection margin, 
extensively positive resection margin or positive resection margin not otherwise specified.Available online http://breast-cancer-research.com/content/8/5/R62
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methods for training and validation are depicted schematically
in Figure 2.
Statistics
All patients who developed a local recurrence were consid-
ered; 16 patients developed a local recurrence as a first event
and in 1 patient local recurrence occurred concurrently with
distant metastases. Local-recurrence-free percentages were
calculated with the Kaplan–Meier method (log-rank test for
comparison). All Kaplan–Meier curves are available as supple-
mentary data in Additional file 5. Comparison of categorical
variables between groups was performed with a χ2 test. For
the multivariable analysis we used a Cox regression model. All
p values are two-sided. All correlations were calculated by the
non-centralized Pearson method. For analysis we used Win-
stat® for Excel (R. Fitch Software, Staufen, Germany), SPSS
13.0® (SPSS Inc., Chicago, IL, USA) and Microsoft Excel®
(Microsoft Corporation) were used. The PAM analysis was
performed with version 1.2 (November 2003) [31,35].
Additional material and methods are available described in
Additional file 9.
Results
In a previously reported series of 295 patients with stage I and
II breast cancer diagnosed at age less than 53 years, 161 had
been treated with BCT (the remaining 134 patients underwent
modified radical mastectomy). Of these 161 patients, 17
developed a local recurrence. From the series of 161 patients,
a training and validation set were selected as described in the
Materials and methods section, distributing local recurrences
equally. This resulted in a balanced distribution of year of treat-
ment and major risk factors for local recurrence between the
two groups as well (Table 1).
Training and validation series
Nine out of 81 patients in the training set had developed a
local recurrence at a median interval of 6.2 years (range 1.0 to
10.8 years); the median follow-up time for the patients in the
entire training set was 7.9 years. Six out of nine local recur-
rence patients had received a boost (five patients received 15
Gy, one patient 25 Gy).
In the validation set, 8 out of 80 patients had developed a local
recurrence at a median interval of 3.72 years (range 1.2 to 8.4
years); the median follow-up time for all patients in the valida-
tion set was 7.6 years. Seven out of these eight patients had
received a boost (three patients received 15 Gy, four patients
25 Gy).
Can a local recurrence classifier be identified by 
supervised classification using all genes?
We used the PAM algorithm with the training data set to
search for gene expression profiles predictive of local recur-
rence, starting with a gene list that consisted of the top 5,000
most variably expressed genes with technically well-measured
expression, represented by microarrays (out of 25,000). The
performance of this approach, as evaluated by cross-valida-
tion, seemed to be poor: only 4 out of 9 local recurrences and
50 of the 72 non-local recurrences could be predicted accu-
rately in the training set at this threshold (using a profile based
on 684 genes). The use of fewer genes resulted in more accu-
rate prediction for non-local-recurrence patients, but less
accuracy for local-recurrence patients. In the validation series
only 1 out of 8 local recurrences and 65 out of 72 non-local
recurrences were predicted correctly (PAM analysis is pro-
vided in Additional files 6, 7, 8).
Using predefined gene sets based on biological 
processes: gene set enrichment analysis
We used the GSEA (gene set enrichment analysis) software
to analyze whether or not gene sets defined on the basis of
biological processes or pathways were significantly correlated
with local recurrence. We first ran the analysis on the full probe
set (more than 23,000). We than ran the analysis on the same
selection of genes used for the PAM analysis (the top 5,000).
Neither the full probe set nor the top 5,000 probe set revealed
any gene set to be significantly upregulated or downregulated
in samples from tumors that recurred locally, after correction
for multiple testing.
Using previously identified gene expression signatures 
to predict local recurrence
We have previously shown that three distinct gene expression
signatures can each be used to subdivide breast carcinomas
into two groups that are associated, respectively, with good
and poor distant-metastasis-free and overall survival: a '70-
Figure 1
Local recurrence Wound-signature correlation plot for the training set Local recurrence Wound-signature correlation plot for the training set. 
Red arrow indicates optimal threshold.Breast Cancer Research    Vol 8 No 5    Nuyten et al.
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gene' prognosis profile [22,23], a wound-response signature
[26,30] and a hypoxia-response signature [27]. We tested
whether these three signatures were also associated with a
difference in the risk of local recurrence. The 70-gene progno-
sis profile was originally trained to predict metastasis within 5
years ('poor prognosis' group) or no metastasis within 5 years
('good prognosis' group); in the current series of 161 patients,
97 patients had tumors with a poor prognosis profile and 64
patients had tumors with a good prognosis profile.
The wound-response signature was derived from an in vitro
model for wound healing and can be used to classify tumors
as having an 'activated wound-response signature' or a 'quies-
cent wound-response signature' [26,30]. In this series of
tumors, 380 (out of 459) genes from the wound-response sig-
nature were identified; 65 tumors had an activated wound-
response signature and 96 tumors had a quiescent wound-
response signature.
The hypoxia-response profile is a gene expression classifier
derived from an ex vivo model in which epithelial cells are
exposed to hypoxia [27]. In this series of tumors, 123 (out of
168) genes from the hypoxia-response signature were identi-
fied. On the basis of the expression of these hypoxia-associ-
Figure 2
Scheme for training and validation, including Kaplan–Meier curves for local-recurrence-free survival Scheme for training and validation, including Kaplan–Meier curves for local-recurrence-free survival.Available online http://breast-cancer-research.com/content/8/5/R62
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ated genes, the breast carcinomas in this study could be
assigned to 36 cases with a hypoxia-response signature and
125 with a non-hypoxia signature.
Of these three signatures, only the wound-response signature
showed some evidence (p = 0.04; log-rank) of predicting local
recurrence (13% versus 19% at 10 years for quiescent versus
activated).
Building a classifier for local recurrence based on 
existing gene selections
Because the supervised approach using all genes (class pre-
diction; PAM) failed and the previously identified gene expres-
sion signatures could not convincingly predict the risk of a
local recurrence, we used genes from the original profiles and
constructed a new classifier based on the relationship of their
expression patterns to clinical outcome observed in our study
(local recurrence or no local recurrence).
Each of these three signatures was originally defined for pur-
poses other than the prediction of local recurrence, but we
hypothesized that the optimization of each signature's pattern
threshold by training on local recurrence data might improve
their performance for this new purpose.
Seventy-gene prognosis profile
Applying the method described in the Materials and methods
section, a correlation value of 0.2364 was calculated as a cut-
off point for the 70-gene expression profile as a predictor of
local recurrence, resulting in one misclassified patient with
local recurrence. The recurrence risks at 10 years were 7%
and 28% for the low-risk and high-risk groups, respectively.
In the validation set the separation could not be reproduced (p
= 0.34; log-rank). The sensitivity was 63% (5 out of 8) and the
specificity 50% (36 out of 72). At 10 years the recurrence risk
was 13% versus 14% for the low-risk group versus the high-
risk group. Furthermore, more than half the patients were
assigned by this classifier to the high-risk group (41/80).
Hypoxia-response signature
For the hypoxia-response gene expression signature, the
threshold that misses one patient with local recurrence
seemed to be 0.254. In the training set the estimated 10-year
recurrence risks for the low-risk and high-risk groups as deter-
mined by using this threshold were 10% and 19%, respec-
tively. The performance of this signature on the validation set
was not significant (p = 0.4). By employing this threshold on
the validation set, 46 patients (58%) were classified as 'high
risk' and 34 (42%) as low risk. At 10 years the recurrence risk
was 13% versus 15% for low-risk versus high-risk, respec-
tively. The sensitivity and specificity were 75% (6 out of 8) and
44% (32 out of 72), respectively.
Wound-response signature: core serum response genes
The wound-response signature was first identified as a pattern
of changes in gene expression induced by exposing fibrob-
lasts to serum. A threshold value of 0.3179 for the correlation
with the wound-response signature (as derived from the 380
available genes) resulted in one missed local recurrence in the
training set. With the use of the threshold value for classifica-
tion, 30 patients (37%) were classified as high-risk, and 51
(63%) as low-risk. In the training set, the 10-year recurrence
risk was 6% for the 'low-risk' group and 35% for the 'high-risk'
group. With this threshold, in the validation set 26 patients
(33%) were classified as high-risk, and 54 (67%) as low-risk.
The 10-year recurrence risk in the validation set was 5% for
the low-risk group, in contrast with 29% for the high-risk group
(p  = 0.0008; log-rank). The predictive performance of the
wound-response local recurrence signature on the validation
set, using the threshold derived from the training set, is shown
in Figure 2. The sensitivity of this classifier for predicting local
recurrence in the validation set was 88% (7 out of 8) with a
specificity of 74% (53 out of 72). The hazard ratio was 15
(95% confidence interval (CI) 1.8 to 123; log-rank 0.01). An
overview of the sensitivity and specificity for the three super-
vised approaches is shown in Table 3.
Cox regression: multivariable analysis
To assess the independent prognostic value of the supervised
wound-response signature, it was tested in a Cox regression
model that also included known clinico-pathological risk fac-
Table 3
Performance of three different supervised analyses on validation series
Analysis WS supervised 70-genes supervised Hypoxia supervised
Sensitivity (percentage) 88 63 75
Specificity (percentage) 74 50 44
Low risk/high riska (percentage) 67/33 49/51 42/58
10-year LC low/high (percentage) 95/71 87/86 87/85
pb 0.0008 0.34 0.4
WS, wound signature; LC, local control.
aIn validation set (percentages; n = 80); bp value in validation set (log-rank).Breast Cancer Research    Vol 8 No 5    Nuyten et al.
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tors for local recurrence, using the independent validation data
set. The factors that independently predicted a local recur-
rence in multivariable analysis in the EORTC 'boost versus no
boost' trial were tested together with the local recurrence clas-
sifiers [17]. In the presence of age, diameter and boost treat-
ment, all the gene expression classifiers were tested. Only the
wound-response local recurrence signature (average local
recurrence centroid) added significant prognostic information
to the classical risk factors in predicting a local recurrence
(hazard ratio 16 (95% CI 1.9 to 125); p  = 0.01). Further
results of the multivariable analysis are shown in Table 4.
Discussion
We have shown that gene expression profiling using DNA-
microarray analysis can be used in risk stratification for local
recurrence after BCT in breast cancer patients. We tested
several different methods: standard supervised analysis (PAM
and GSEA, with local recurrence as the end point), profiles
that have previously been used to predict distant metastasis
and survival, and a combination of both approaches by super-
vising these previously established predictive profiles with clin-
ical data on local recurrence.
The supervised wound-response signature derived by this
approach is the only profile that could predict a local recur-
rence after BCT. This new method begins with a biologically
defined gene set and constructs a classifier by a supervised
learning procedure from the expression pattern of the selected
gene set, using clinical data. This thereby uses not only the
genes themselves but also the expression levels for the differ-
ent genes in the signature that are correlated with the clinical
end point (local recurrence). The power of this signature in
predicting local recurrence was highly significant, even if we
conservatively take into account the fact that we tried a total of
seven methods, by applying a Bonferroni correction to the p
value of 0.0008 associated with the supervised wound signa-
ture. It is important to note that the gene set derived from an in
vitro model, the wound response, but not the wound-response
gene expression signature itself, was adapted to derive a gene
expression pattern predictive of a local recurrence in patients
who were treated with BCT.
Gene expression profiling has been successfully applied to
distinguish molecular subtypes in breast cancer and to predict
metastases and overall survival [19-23,25]. More recently,
gene expression profiling has also been used in trying to iden-
tify signatures predicting response to neo-adjuvant chemo-
therapy treatment [36,37], and prognosis after treatment with
tamoxifen [38-41]. Because many patients are suitable candi-
dates for breast conservation on the basis of low baseline risk
for developing a local recurrence, this treatment has become
standard for more than 60% of breast cancer patients. A
recently published pooled analysis shows that local recur-
rence is associated with an increased risk of developing dis-
tant metastases and subsequent death from breast cancer
[42]. These findings are similar to the recently published
EBCTCG (the Early Breast Cancer Trialists' Collaborative
Group) meta-analysis [9]. After BCT without radiotherapy, an
absolute increase of 5.4% in breast cancer mortality was seen.
Moreover, local recurrence requires treatment (usually salvage
mastectomy) and is associated with anxiety for affected
patients. It is therefore important to tailor BCT in such a way
that the risk of local recurrence is kept as low as possible,
while optimizing the quality of life, including the cosmetic
appearance of the breast. To select patients who are likely to
benefit from BCT, clinico-pathological parameters are cur-
rently used to stratify patients by risk of local recurrence.
These existing prognostic factors are far from perfect, and
additional or better predictors of local recurrence would be of
great potential benefit. Aggressive treatment including a larger
excision volume and/or a higher local radiotherapy dose
('boost') significantly decreases the risk at of local recurrence
but results in impaired cosmetic outcome [43]. In patients con-
sidered to be at low risk of local recurrence, the boost dose
could be forgone and in patients with a high risk a boost
should be administered or even escalated. Furthermore, for
patients at very high risk of local recurrence a primary mastec-
tomy can be offered.
Because the number of patients and the number of local recur-
rence events was low in this study, these results must be inter-
preted with caution. Although the hazard ratio for a local
recurrence in the validation series is high (15), the confidence
Table 4
Cox regression analysis on local recurrence: clinical risk factors and wound signature (validation series only)
Risk factor Significance Hazard ratio for local recurrence 95% CI for hazard ratio
Lower Upper
Age <40 years 0.39 2.542 0.30 21.7
Tumor size T2/T1 0.57 1.683 0.31 9.1
Boost treatment no/yes 0.83 1.343 0.09 20.2
Wound signature high risk/low risk 0.01 16 1.9 125
CI: confidence interval.Available online http://breast-cancer-research.com/content/8/5/R62
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interval is wide (by univariate analysis, 95% CI 1.8 to 123).
Given the potential contribution of this prognostic signature to
improve decision making in planning the treatment of breast
cancer and an improved understanding of the pathogenesis of
local recurrence, an independent test of its predictive value is
a high priority. Recently, in The Netherlands, a randomized
clinical trial started, to compare the standard radiotherapy
dose (50 Gy whole breast and 16 Gy boost to the tumor bed)
with an additional boost dose (26 Gy). In this trial, fresh frozen
tumor samples will be collected. This trial will allow prospec-
tive validation of the signature.
Conclusion
We have presented a method of integrating biologically
derived gene expression profiles and clinical data to build a
classifier for local recurrence after breast-conserving therapy.
Although numbers of events are small and the resulting confi-
dence intervals are wide, it is the first classifier based on
microarray analysis to specifically predict a local recurrence
after breast-conserving therapy. In our series the classifier is
the most powerful predictor and is independent of clinical and
pathological variables.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DSAN conceived the method of building the gene expression
profile specifically for local recurrence and performed the pri-
mary analysis. DSAN, BK, AAMH, JTAC, JBC, LFW, HJP, HB,
POB, HYC and MJvdV analyzed and interpreted data. DSAN,
AAMH and MJvdV wrote the paper. All authors read and
approved the final manuscript.
Additional files
The following Additional files are available online:
Additional file 1
An Excel file containing all clinical data, including all 
labels for various classifiers (both the original previously 
published labels as well as the local recurrence labels), 
and the correlation values (to the local recurrence 
centroids) for all patients.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S1.xls
Additional file 2
An Excel file containing the expression data for the 70 
genes for all patients (training (local recurrence and non-
local recurrence) and validation set separately) and the 
calculated 70 genes local recurrence centroid data and 
correlation values for all patients to this centroid.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S2.xls
Additional file 3
An Excel file containing the expression data for the 
hypoxia genes for all patients (training (local recurrence 
and non-local recurrence) and validation set separately) 
and the calculated hypoxia local recurrence centroid 
data and correlation values for all patients to this 
centroid.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S3.xls
Additional file 4
An Excel file containing the expression data for the 
wound signature genes for all patients (training (local 
recurrence and non local recurrence) and validation set 
separately) and the calculated wound signature local 
recurrence centroid data and correlation values for all 
patients to this centroid.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S4.xls
Additional file 5
An Excel file containing all Kaplan–Meier curves for the 
original classification and the supervised classifications.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S5.xls
Additional file 6
A text file containing the expression data for the 5,000 
most variable expressed genes on the array for all 
patients in the training set.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S6.txt
Additional file 7
A text file containing the expression data for the 5,000 
most variable expressed genes on the array for all 
patients in the validation set.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S7.txt
Additional file 8
An Excel file containing the results from the PAM 
analysis.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S8.xls
Additional file 9
A Word file containing supplementary additional details 
of material and methods.
See http://www.biomedcentral.com/content/
supplementary/bcr1614-S9.docBreast Cancer Research    Vol 8 No 5    Nuyten et al.
Page 10 of 11
(page number not for citation purposes)
Acknowledgements
This work was supported by Dutch Cancer Society Grant NKB 2002-
2575 (to DSAN, BK, HB and MJvdV), National Institutes of Health 
Grants CA77097 and CA85129 (to POB) and AR050007 (to HYC), 
and a National Science Foundation Predoctoral Fellowship (to JBS). 
POB is an Investigator of the Howard Hughes Medical Institute.
References
1. Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spiel-
mann M, Rochard F, Le Chevalier T, Lacour J: Ten-year results of
a randomized trial comparing a conservative treatment to
mastectomy in early breast cancer.  Radiother Oncol 1989,
14:177-184.
2. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK,
Andersen KW, Mouridsen HT: Danish randomized trial compar-
ing breast conservation therapy with mastectomy: six years of
life-table analysis. Danish Breast Cancer Cooperative Group.
J Natl Cancer Inst Monogr 1992, 11:19-25.
3. Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi
P, Salvadori B, Zucali R: Radiotherapy after breast-conserving
surgery in small breast carcinoma: long-term results of a ran-
domized trial.  Ann Oncol 2001, 12:997-1003.
4. Mariani L, Salvadori B, Marubini E, Conti AR, Rovini D, Cusumano
F, Rosolin T, Andreola S, Zucali R, Rilke F, Veronesi U: Ten year
results of a randomised trial comparing two conservative
treatment strategies for small size breast cancer.  Eur J Cancer
1998, 34:1156-1162.
5. Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio
M, Mariani L, Zurrida S, Rilke F: Breast conservation is a safe
method in patients with small cancer of the breast. Long-term
results of three randomised trials on 1,973 patients.  Eur J Can-
cer 1995, 31A:1574-1579.
6. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ,
Tong D, van der SE, Helle PA, van Zijl K, Bartelink H: Long-term
results of a randomized trial comparing breast-conserving
therapy with mastectomy: European Organization for
Research and Treatment of Cancer 10801 trial.  J Natl Cancer
Inst 2000, 92:1143-1150.
7. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher
ER, Jeong JH, Wolmark N: Twenty-year follow-up of a rand-
omized trial comparing total mastectomy, lumpectomy, and
lumpectomy plus irradiation for the treatment of invasive
breast cancer.  N Engl J Med 2002, 347:1233-1241.
8. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Bli-
chert-Toft M, Melbye M: Effect of breast-conserving therapy ver-
sus radical mastectomy on prognosis for young women with
breast carcinoma.  Cancer 2004, 100:688-693.
9. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E,
Godwin J, Gray R, Hicks C, James S, et al.: Effects of radiother-
apy and of differences in the extent of surgery for early breast
cancer on local recurrence and 15-year survival: an overview
of the randomised trials.  Lancet 2005, 366:2087-2106.
10. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H,
Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van
Dongen JA: Differences in risk factors for local and distant
recurrence after breast-conserving therapy or mastectomy for
stage I and II breast cancer: pooled results of two large Euro-
pean randomized trials.  J Clin Oncol 2001, 19:1688-1697.
11. Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bar-
telink H: Risk factors in breast-conservation therapy.  J Clin
Oncol 1994, 12:653-660.
12. Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de
Velde CJ, van den Broek LC, van de Vijver MJ: High local recur-
rence risk after breast-conserving therapy in node-negative
premenopausal breast cancer patients is greatly reduced by
one course of perioperative chemotherapy: a European
Organization for Research and Treatment of Cancer Breast
Cancer Cooperative Group Study.  J Clin Oncol 2000,
18:1075-1083.
13. Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwel-
ingen HC, Leer JW, van de Vijver MJ: Risk factors for local recur-
rence after breast-conserving therapy for invasive carcinomas:
a case-control study of histological factors and alterations in
oncogene expression.  Int J Radiat Oncol Biol Phys 1999,
45:73-83.
14. Fredriksson I, Liljegren G, Palm-Sjovall M, Arnesson LG, Emdin
SO, Fornander T, Lindgren A, Nordgren H, Idvall I, Holmqvist M, et
al.: Risk factors for local recurrence after breast-conserving
surgery.  Br J Surg 2003, 90:1093-1102.
15. Voogd AC, Peterse JL, Crommelin MA, Rutgers EJ, Botke G,
Elkhuizen PH, van Geel AN, Hoekstra CJ, van Pel R, van de Vijver
MJ, Coebergh JW: Histological determinants for different types
of local recurrence after breast-conserving therapy of invasive
breast cancer. Dutch Study Group on local Recurrence after
Breast Conservation (BORST).  Eur J Cancer 1999,
35:1828-1837.
16. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R,
Silver B, Hetelekidis S, Abner A, Harris J, Schnitt S: Outcome at
8 years after breast-conserving surgery and radiation therapy
for invasive breast cancer: influence of margin status and sys-
temic therapy on local recurrence.  J Clin Oncol 2000,
18:1668-1675.
17. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC,
Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, et al.:
Can patient-, treatment- and pathology-related characteristics
explain the high local recurrence rate following breast-con-
serving therapy in young patients?  Eur J Cancer 2003,
39:932-944.
18. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den
Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad
W, et al.: Recurrence rates after treatment of breast cancer
with standard radiotherapy with or without additional radia-
tion.  N Engl J Med 2001, 345:1378-1387.
19. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular por-
traits of human breast tumours.  Nature 2000, 406:747-752.
20. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng
S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation
of breast tumor subtypes in independent gene expression
data sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.: Gene expres-
sion patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications.  Proc Natl Acad Sci USA
2001, 98:10869-10874.
22. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M,
Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene
expression profiling predicts clinical outcome of breast can-
cer.  Nature 2002, 415:530-536.
23. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al.: A gene-
expression signature as a predictor of survival in breast can-
cer.  N Engl J Med 2002, 347:1999-2009.
24. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A,
Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification
and prognosis based on gene expression profiles from a pop-
ulation-based study.  Proc Natl Acad Sci USA 2003,
100:10393-10398.
25. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F,
Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.:
Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer.  Lancet 2005,
365:671-679.
26. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie
T, Dai H, He YD, van't Veer LJ, Bartelink H, et al.: Robustness,
scalability, and integration of a wound-response gene expres-
sion signature in predicting breast cancer survival.  Proc Natl
Acad Sci USA 2005, 102:3738-3743.
27. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A,
Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, et al.:
Gene expression programs in response to hypoxia: cell type
specificity and prognostic significance in human cancers.
PLoS Med 2006, 3:e47.
28. The van de Vijver Lab   [http://research.nki.nl/vandevijverlab/]
29. Predicting a local recurrence after breast conserving therapy
by gene expression profiling   [http://microarray-pubs.stan
ford.edu/wound_local_recurrence]
30. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Mont-
gomery K, Chi JT, Rijn Mv M, Botstein D, Brown PO: Gene expres-
sion signature of fibroblast serum response predicts humanAvailable online http://breast-cancer-research.com/content/8/5/R62
Page 11 of 11
(page number not for citation purposes)
cancer progression: similarities between tumors and wounds.
PLoS Biol 2004, 2:E7.
31. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multi-
ple cancer types by shrunken centroids of gene expression.
Proc Natl Acad Sci USA 2002, 99:6567-6572.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES,
Mesirov JP: Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles.
Proc Natl Acad Sci USA 2005, 102:15545-15550.
33. Gene Set Enrichment Analysis: overview   [http://
www.broad.mit.edu/gsea/]
34. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM,
Staudt LM, Hudson J Jr, Boguski MS, et al.: The transcriptional
program in the response of human fibroblasts to serum.  Sci-
ence 1999, 283:83-87.
35. PAM: Prediction Analysis for Microarrays   [http://www-
stat.stanford.edu/~tibs/PAM/index.html]
36. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K,
Lecocke M, Metivier J, Booser D, Ibrahim N, et al.: Gene expres-
sion profiles predict complete pathologic response to neoad-
juvant paclitaxel and fluorouracil, doxorubicin, and
cyclophosphamide chemotherapy in breast cancer.  J Clin
Oncol 2004, 22:2284-2293.
37. Chang JC, Wooten E, Tsimelzon A, Hilsenbeck S, Gutierrez MC,
Elledge R, Mohsin S, Osborne CK, Chamness G, Allred DC,
O'Connell P: Gene expression profiling for the prediction of
therapeutic response to docetaxel in patients with breast can-
cer.  Lancet 2003, 362:362-369.
38. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Rit-
stier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen
H, Dorssers LC, et al.: Molecular classification of tamoxifen-
resistant breast carcinomas by gene expression profiling.  J
Clin Oncol 2005, 23:732-740.
39. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen
L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J: Tamoxifen
resistance by a conformational arrest of the estrogen receptor
alpha after PKA activation in breast cancer.  Cancer Cell 2004,
5:597-605.
40. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir
B, Mohapatra G, Salunga R, Tuggle JT, et al.: A two-gene expres-
sion ratio predicts clinical outcome in breast cancer patients
treated with tamoxifen.  Cancer Cell 2004, 5:607-616.
41. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL,
Walker MG, Watson D, Park T, et al.: A multigene assay to pre-
dict recurrence of tamoxifen-treated, node-negative breast
cancer.  N Engl J Med 2004, 351:2817-2826.
42. Vinh-Hung V, Verschraegen C: Breast-conserving surgery with
or without radiotherapy: pooled-analysis for risks of ipsilateral
breast tumor recurrence and mortality.  J Natl Cancer Inst
2004, 96:115-121.
43. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC,
Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M,
et al.: The influence of the boost in breast-conserving therapy
on cosmetic outcome in the EORTC 'boost versus no boost'
trial. EORTC Radiotherapy and Breast Cancer Cooperative
Groups. European Organization for Research and Treatment
of Cancer.  Int J Radiat Oncol Biol Phys 1999, 45:677-685.